Clinion AI responds to growing demand to serve remote clinical trials

The demand for eClinical solutions to monitor and collect data in clinical trials is driving a market with a projected CAGR of 12.8% between now and 2032. It is a market Clinion IT Services is keen to serve, supporting the testing of new drugs and medical devices.

eClinical solutions include software, services, and solutions for clinical trials. Clinical trials used to be managed by in-person visits with manual data collection and analysis. Improvements in technology plus the pandemic’s limitations on person-to-person contact drove demand for eClinical solutions.

Responding to this shift, Clinion introduced Clinion AI, an integrated eClinical platform. It enables pharmaceutical, biotech, and medical device firms to accelerate trial setup and conduct and manage trials virtually and more efficiently than manual in-person approaches. Its platform, Clinion AI (see Exhibit 1), includes eClinical solutions such as Electronic Data Capture (EDC), Randomisation and Trial Supply Management (RTSM), Patient Reported Outcomes (ePRO), and Clinical Trial Management Systems (CTMS). Clinion is a SaaS platform running on Microsoft Azure and AWS clouds.

Regulators open the way for eClinical expansion

Regulatory firms worldwide, such as the US Food and Drug Administration (USFDA), EMA, and the Drugs Controller General of India (DCGI), have become more comfortable with remote eClinical trial software, encouraging its adoption. In 2016, the USFDA set expectations for decentralized eClinical solutions that paved the path for decentralized trials.

Exhibit 1: Clinion AI’s range of eClinical solutions makes it an end-to-end platform solution

Source: Clinion, HFS Research 2023

Clinion’s platform proved its value in the clinical trial process during the pandemic. It was used in Bharat Biotech’s COVID-19 vaccine (Covaxin) and Sputnik V trials. It has been used in more than 70 COVID-19 studies and more than 17 vaccine trials. The platform has enabled more than 17,000 patients to participate in COVID-19 studies remotely.

The number of clinical trials on the Clinion platform grew at a 65% CAGR between 2017 and 2022, with more than 115 clinical trials on the platform in 2021 and 2022. The firm’s primary focus is India, where 80% of its clients are based. However, Clinion has expanded to other regions, including the United States, Canada, Europe, Russia, and Australia, in recent years, accounting for an additional 20% of its business.

Clinion has been solving challenges in the clinical trial industry and its strengths and development opportunities, as shown in Exhibit 2.

Exhibit 2: eClinion platforms show much promise for its customers

Source: Clinion, HFS Research, 2023

The Bottom Line: Integrating various eClinical solutions will drive demand for end-to-end clinical platforms and increase the adoption of decentralized clinical trials.

As clinical trials advance, the demand for efficient remote clinical trial management software will keep growing. Due to its remote capabilities, there have increased acceptance of eClinical solutions. Within the fragmented eClinical solutions market, consolidation may happen, and the platform that offers a comprehensive approach to managing clinical trials, data collection, analysis, and reporting, will be the winner.